

Frequency of virulence factors in *Helicobacter pylori*-infected patients with gastritis



Loghman Salimzadeh ^a, Nader Bagheri ^b, Behnam Zamanzad ^a,
Fateme Azadegan-Dehkordi ^a, Ghorbanali Rahimian ^c,
Morteza Hashemzadeh-Chaleshtori ^a, Mahmoud Rafeian-Kopaei ^d,
Mohammad Hossein Sanei ^e, Hedayatollah Shirzad ^{a,*}

^a Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran

^b Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

^c Department of Internal Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran

^d Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran

^e Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran

ARTICLE INFO

Article history:

Received 25 September 2014

Received in revised form

21 January 2015

Accepted 22 January 2015

Available online 3 February 2015

Keywords:

Helicobacter pylori

Virulence factors

Gastritis

PCR

ABSTRACT

The outcome of *Helicobacter pylori* infection has been related to specific virulence-associated bacterial genotypes. The vacuolating cytotoxin (*vacA*), *cagA* gene, *oipA* and *babA2* gene are important virulence factor involving gastric diseases. The objective of this study was to assess the relationship between virulence factors of *H. pylori* and histopathological findings.

Material and methods: Gastroduodenoscopy was performed in 436 dyspeptic patients. Antrum biopsy was obtained for detection of *H. pylori*, virulence factors and for histopathological assessment. The polymerase chain reaction was used to detect virulence factors of *H. pylori* using specific primers.

Results: *vacA* genotypes in patients infected with *H. pylori* were associated with *cagA*, *iceA1* and *iceA2*. In the patients with *H. pylori* infection there was a significant relationship between *cagA* positivity and neutrophil activity ($P = 0.004$) and chronic inflammation ($P = 0.013$) and with *H. pylori* density ($P = 0.034$). Neutrophil infiltration was found to be more severe in the s1 group than in the s2 group ($P = 0.042$). Also was a significant relationship between *oipA* positivity and neutrophil activity ($P = 0.004$) and with *H. pylori* density ($P = 0.018$). No significant relationships were observed between other *vacA* genotypes and histopathological parameters.

Conclusion: *H. pylori* strains showing *cagA*, *vacA* s1 and *oipA* positivity are associated with more severe gastritis in some histological features but virulence factors of *H. pylori* do not appear to determine the overall pattern of gastritis.

© 2015 Elsevier Ltd. All rights reserved.

1. Introduction

Helicobacter pylori (*H. pylori*) is an important human pathogen that colonize the stomach. This bacterium induces gastritis, peptic ulcer and is associated with gastric carcinoma [1,2]. The clinical outcome of *H. pylori* infection has been associated with bacterial virulence factors, host gastric mucosal factors, and the environment [3]. But relationship between *H. pylori* genotype and its association with clinical outcome is not fully understood. Several possible

disease-specific virulence factors have been suggested to be associated with *H. pylori* infection [4–7]. The main bacterial virulence factors include adhesins (BabA, SabA), the vacuolating cytotoxin VacA, and the products of the *cag* pathogenicity island (*cag* PAI). *CagA* was the most examined putative virulence factor and it is encoded by the *cagA* gene. A number of studies have confirmed that infection with *cagA*-positive strains is associated with more severe gastritis and higher prevalence of peptic ulcer and gastric cancer in western countries [8,9]. Conversely, relationship between *cagA*-positive status and its association with clinical outcome are not fully understood in Asian countries, where the majority of the *H. pylori* strains are *cagA*-positive [10–12]. The vacuolating cytotoxin A gene, which is another important virulence factor of

* Corresponding author.

E-mail addresses: shirzadeh@SKUMS.ac.ir, shirzad1951@yahoo.com (H. Shirzad).

H. pylori, the *vacA* is present in all *H. pylori* strains and induces vacuolation of epithelial cells [8]. The *vacA* gene includes two variable parts. The *H. pylori* strains have one of two types of *vacA* signal sequence (s1 and s2) and two types of mid region (m1 and m2). Cytotoxin production and virulence are higher in the s1/m1 subtypes than in the s1/m2 subtype, and lower still in the s2/m2 subtype [13]. Similar *cagA* status, there are geographic differences between *vacA* status and the *H. pylori*-related diseases. In western countries infection with *vacA* s1 strain is more common in patients with peptic ulcer than in those with chronic gastritis. However in Asian countries, the association between *vacA* diversity and clinical outcome is not established [14]. BabA is an adhesion molecule that mediates the attachment of *H. pylori* to Lewis b blood group antigens on human gastric epithelial cells [15]. Three bab alleles have been identified: babA1, babA2, and babB and only the babA2 gene product is necessary for Lewis b binding activity [15]. Studies in western countries have shown that about 70% of *H. pylori* strains in Western countries were typed as babA2, which was associated with increased virulence [16]. Moreover, the triple-positive phenotype (babA2, *cagA*, and *vacA* s1) was detected at a higher frequency in isolates from patients with ulcers and adenocarcinomas, which might serve as useful markers of high-risk patients in western countries [16]. The *iceA* gene is induced by contact with epithelium and has two main allelic variants, *iceA*1 and *iceA*2. The presence of *iceA*1 allele is associated with peptic ulcer disease in western countries [17]. OipA is a proinflammatory response-inducing protein associated with high *H. pylori* density and more severe neutrophil infiltration. OipA mediates adherence of *H. pylori* to gastric epithelial cells and contributes to the pathogenesis of gastroduodenal diseases [18]. Therefore, the aim of this study was to analyze the frequency of virulence factors and to correlate the presence of babA2 with *cagA*, *oipA* and *vacA*, *iceA* genotypes of

H. pylori strains in Iran patients and to study its association with the histologic severity of gastritis.

2. Materials and methods

2.1. Study population

The subjects included in this study were 436 patients with non-ulcer dyspepsia (NUD) (195 patients with *H. pylori* infection and 241 *H. pylori* uninfected), having recurrent abdominal pain from endoscopy unit of the Hajar Hospital in Shahrekord, Iran. From each patient, written consent was obtained and 3 biopsies were collected from gastric antrum. Two specimens were used for rapid urease test and DNA extraction, and one specimen was used for histopathology study. *H. pylori*-infection was determined by the rapid urease test, PCR (16sRNA and glmM) and histological examination of biopsies taken from the corpus. Patients were classified as *H. pylori*-infected only if the four tests were positive, respectively. This study was performed by the Ethics Committee approval No: 1025 of Shahrekord University of Medical Sciences, Shahrekord, Iran.

2.2. Histological examination

Sections of biopsy specimens were embedded in 10% buffered formalin and stained with hematoxylin and eosin to examine gastritis and with giemsa to detect *H. pylori* (Fig. 1). The histological severity of gastritis was blindly graded from normal to severe based on the degree of mononuclear cell (MNC) and polymorphonuclear leukocyte (PMN) infiltration, and atrophy according to the Updated Sydney system [19] on a four-point scale: 0, no; 1, mild; 2, moderate; and 3, severe changes.




Fig. 1. Histological examination. (A) Mild chronic superficial gastritis with chronic inflammatory cells present in the superficial lamina propria in excess of normal. This is a borderline biopsy sample and illustrates the least number of cells acceptable for a diagnosis of gastritis. (B) Gastric pits infiltrated by neutrophils in a case of *Helicobacter pylori* gastritis. (C) *H. pylori* organisms present in the mucous layer on the gastric mucosal surface (400 \times).

Table 1
Demographic data of study subjects.

Variable	<i>H. pylori</i> infected (%)	<i>H. pylori</i> uninfected (%)	P Value
Total	195 (44.4%)	241 (55.6%)	0.56
Gender			
Male	80 (41.9%)	106 (58.1%)	
Female	115 (46.2%)	136 (53.8%)	
Mean \pm SD (year)	46.74 \pm 16.79	48.56 \pm 19.82	0.298

2.3. DNA extraction and detection of virulence factors by PCR

DNA for polymerase chain reaction (PCR) was extracted using the Biospin Tissue Genomic DNA Extraction Kit (BioFlux, Japan). Detection of virulence factors was performed by PCR and reported by bagheri et al. [4,20]. For *vacA*, *cagA*, *iceA* and *babA2* evaluation, the PCR program comprised 35 cycles of denaturation (at 94 °C for 30 s), annealing (at 56 °C for 30 s, extension at 72 °C for 30 s), and one final extension (at 72 °C for 5 min). For *oipA*, amplification was performed with 35 cycles of denaturation (at 94 °C for 30 s, annealing at 60 °C for 30 s, extension at 72 °C for 30 s), and one final extension (at 72 °C for 5 min).

2.4. Statistical analysis

All data are expressed as mean \pm SEM. Age was analyzed by unpaired Student's T-Test. The Chi-squared (χ^2) and Fisher's exact test were used for analyzing categorical variables data and to compare differences in the prevalence of *H. pylori* genotypes. Statistical analysis of the data was carried out by SPSS, version 16, statistical software program and ANOVA was used for continuing data. A *P* values <0.05 were considered to be statistically significant.

3. Results

The characteristics of the population studied are listed in Table 1. There was no significant difference between *H. pylori* infected and *H. pylori* uninfected subjects with respect to the age and gender distribution. Also Fig. 2 shows the results of electrophoresis of PCR products.

3.1. Genotypes

Results of PCR product indicating the presence of the *cagA* gene was obtained with 139 patients with *H. pylori* infection (71.2%) and




Fig. 2. *H. pylori* diagnostic by PCR and *vacA*, *cagA*, *iceA1/2*, *oipA* and *babA2* genotypes. (A) and (B) *H. pylori* diagnostic: (A) M, 100-bp ladder marker. (2–6) 109 bp *H. pylori* 16S rRNA and (B) M, 100-bp ladder marker. (2–6) 294 bp *H. pylori* glmM. (C) *H. pylori vacA* (middle sequence) genotype: M, 100-bp ladder marker. 567 bp (m1 allele); 642 bp (m2 allele) and *vacA* (signal sequence) genotype: 259 bp (s1 allele); 286 bp (s2 allele). (D) *H. pylori cagA* genotype: M, 100-bp ladder marker. (2–6) 232 bp, *cagA*-positive strains. (E) *H. pylori babA2* genotype: M, 100-bp ladder marker. (2–6) 271 bp, *babA2*-positive strains. (F) *H. pylori iceA1* genotype: M, 100-bp ladder marker. (2–5) 247 bp, *iceA1*-positive strains. (G) *H. pylori iceA2* genotype: M, 100-bp ladder marker. (1 and 3–6) 229 or 334 bp, *iceA2*-positive strains. (H) *H. pylori oipA* genotype: M, 100-bp ladder marker. (2–6) 430 bp, *oipA*-positive strains.

Table 2
Prevalence of *H. pylori* genotypes detected in patients.

Genotype	Prevalence
cagA	
cagA positive	139 (71.2%)
cagA negative	56 (28.8%)
vacA	
s1 positive	151 (77.4%)
s2 positive	30 (15.3%)
s1s2 positive	9 (4.6%)
s1s2 negative	5 (2.5%)
m1 positive	48 (24.6%)
m2 positive	125 (64.1%)
m1m2 positive	18 (9.2%)
m1m2 negative	4 (2.0%)
s1m1	55 (28.2%)
s1m2	79 (40.5%)
s2m1	29 (14.8%)
s2m2	0 (00.0%)
Other genotype	32 (16.4%)
iceA	
iceA1 positive	100 (51.2%)
iceA2 positive	61 (31.2%)
iceA1/iceA2 positive	16 (8.2%)
iceA1/iceA2 negative	18 (9.2%)
oipA	
oipA positive	187 (95.9%)
oipA negative	8 (4.1%)
babA2	
babA2 positive	168 (86.1%)
babA2 negative	27 (13.9%)

56 (28.8%) were negative (Table 2). In the m-region, 18 patients (9.2%) contained both m1 and m2 alleles. In the patients containing one single vacA m allele, the m1 allele was found in 48 patients (24.6%) and m2 in 125 one (64.1%). In the s-region, 9 patients (4.6%) contained both m1 and m2 alleles. In the patients containing one single vacA s allele, the s1 allele was found in 151 patients (77.4%) and s2 in 30 one (15.3%). The vacA genotype s1/m1, s1m2 and s2m1 were detected in 55 (28.2%), 79 (40.5%) and 29 (14.8%) patients. The s2m2 genotype was not found in our study. The oipA and babA2 genes were detected in 187 (95.9%) and 168 (86.1%) patients. Overall, iceA1 was detected in 100 patients (51.2%) of all 281 patients and iceA2 was found in 61 patients (31.2%). 16 patients (8.2%) were positive for both iceA1 and iceA2 and 18 patients (9.2%) were negative for both iceA1 and iceA2 (Table 2).

3.2. Correlation of vacA alleles and presence virulence factors

The cagA gene was detected in 139 (71.2%) patients with *H. pylori* infection. The association between vacA alleles and presence virulence factors is described in Table 3. Of the 139 patients infected with *H. pylori* that were positive for cagA, 115 patients were

associated with the toxin-producing vacA s1 and only 33 patients with cagA-positive were vacA s2. Of the 139 patients with *H. pylori* infection that were positive for cagA, 43 patients were associated with vacA s1m1, 61 patients were associated with vacA s1m2 and only 13 patients with cagA-positive were vacA s2m2. Also vacA genotypes in patients infected with *H. pylori* were associated with iceA1 and iceA2 (Table 3).

3.3. *H. pylori* density

The density of *H. pylori* was scored in gastric biopsy specimens. The density scores of *H. pylori* in patients with cagA and oipA positive were higher than in the cagA and oipA negative (Table 4). There was no significant relationship between other virulence factors and *H. pylori* density.

3.4. Neutrophil activity

CagA, oipA and vacA s1 positive genotypes were strongly associated with higher neutrophil activity in gastric biopsy specimens (Table 4). No relationships were found between neutrophil activity and other virulence factors in gastric biopsy specimens.

3.5. Chronic inflammation

There was an association between cagA positivity and high inflammation scores in gastric biopsy specimens ($p = 0.013$). There was no relationship between other virulence factors and chronic inflammation in gastric biopsy specimens (Table 4).

4. Discussion

H. pylori infection results in chronic gastritis and, eventually, diseases, such as peptic ulcer, gastric cancer, and MALT lymphoma [1,3]. Genotypic alterations of *H. pylori* are thought to be responsible for the various clinical manifestations and for infection without symptoms or with symptoms of gastric carcinoma and MALT lymphoma. In our study, the presence of virulence factors, which is thought to be associated with severe diseases, was investigated in patients with functional dyspepsia and compared with histological findings. Although an association between *H. pylori* infection and chronic gastritis is clear, development of severe gastric diseases is rare. These variations in the clinical consequences are because of factors such as duration of the infection, inflammatory response of the patient, virulence of *H. pylori* strains. Infection with less virulent strains is associated with mild symptoms whereas infection with more virulent strains is thought to be associated with more severe gastric inflammation and, eventually, peptic ulcer, gastric adenoma, and MALT lymphoma. The

Table 3
Correlation of vacA alleles with the cagA, babA2, and iceA genotype of the samples studied.

vacA genotype	cagA		babA2		iceA1		iceA2	
	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative
s1m1	43	9	48	5	37	16	16	37
s1m2	61	19	63	17	48	32	34	46
s2m2	13	16	26	3	9	20	17	12
P value	0.001		0.128		0.003		0.042	
s1	115	33	125	23	96	52	52	96
s2	13	17	27	3	10	20	17	13
P value	0.000		0.576		0.001		0.027	
m1	43	10	48	5	38	15	15	38
m2	78	40	98	20	61	57	57	61
P value	0.046		0.198		0.014		0.014	

Table 4

Relationship between histological parameters determined in gastric biopsy specimens and *H. pylori* cagA status.

Genotype	Neutrophil activity ^a	Chronic inflammation ^a	<i>H. pylori</i> density
cagA (+)	0.99 (0–3)	1.88 (0–3)	1.80 (0–3)
cagA (–)	0.59 (0–3)	1.61 (0–3)	1.56 (0–3)
<i>p</i> ^b	0.004	0.013	0.034
vacA m1	1.00 (0–3)	1.75 (0–3)	1.51 (0–3)
vacA m2	0.79 (0–3)	1.50 (0–3)	1.49 (0–3)
	0.135	0.057	0.869
vacA s1	0.94 (0–3)	1.61 (0–3)	1.47 (0–3)
vacA s2	0.59 (0–3)	1.34 (0–3)	1.47 (0–3)
<i>p</i> ^b	0.042	0.1	0.998
s1m1	1.00 (0–3)	1.72 (0–3)	1.55 (0–3)
s1m2	0.88 (0–3)	1.56 (0–3)	1.54 (0–3)
s2m2	0.59 (0–3)	1.28 (0–3)	1.53 (0–3)
<i>p</i> ^b	0.06	0.576	0.996
iceA1 (+)	0.86 (0–3)	1.64 (0–3)	1.54 (0–3)
iceA1 (–)	0.90 (0–3)	1.44 (0–3)	1.42 (0–3)
<i>p</i> ^b	0.787	0.079	0.236
iceA2 (+)	0.85 (0–3)	1.53 (0–3)	1.55 (0–3)
iceA2 (–)	0.90 (0–3)	1.57 (0–3)	1.45 (0–3)
<i>p</i> ^b	0.658	0.731	0.309
babA2 (+)	0.89 (0–3)	1.57 (0–3)	1.51 (0–3)
babA2 (–)	0.81 (0–3)	1.44 (0–3)	1.41 (0–3)
<i>p</i> ^b	0.673	0.431	0.475
oipA (+)	0.91 (0–3)	1.55 (0–3)	1.51 (0–3)
oipA (–)	0.25 (0–3)	1.62 (0–3)	1.12 (0–3)
<i>p</i> ^b	0.032	0.797	0.018

^a The histopathological parameters were scored as: 0, none; 1, mild; 2, moderate; 3, severe.

^b Mean scores were compared with the *t* test.

relationship between *H. pylori* genotypes and infection with gastric inflammatory response varies within nationalities. In Western countries it has been demonstrated that more severe gastric inflammation develops after infection with cagA-positive strains; in Asian countries there is no such difference. Studies from Turkey on cagA positivity and the histopathological findings of gastritis led to conflicting results. Demirturk et al. suggested that cagA positivity is associated with more severe glandular atrophy, inflammation, and activity, whereas Saruc et al. demonstrated a relationship between cagA positivity with inflammation, *H. pylori* density, and intestinal metaplasia but not with glandular atrophy [21,22]. In our study, we found 71.2% infected patients with cagA-positive which are similar to some reports from Iran [23] and different from reports of South and East Asian where the presence of cagA strain and its association with clinical outcomes is more than 90% [24,25]. It has been shown that the prevalence of cagA-positive strains in USA and Europe is 60–70% [26]. Our results also demonstrate that cagA-positive patients showed more severe neutrophil infiltration, chronic inflammation and *H. pylori* density in patients infected with *H. pylori*. The variability of the vacA s and m regions is thought to have effects over the secretion of vacuolating toxin. s1/m1 strains produce huge amounts of toxins and are highly detrimental. s2 strains do not produce such toxins. In many studies, the variability of the s genotypes is associated with disease formation but not proven. In our study, we find that there is statistically significant relationship between vacA s1 genotype and neutrophil infiltration. Warburton et al. reported no relationship between vac s1 and s2 regions and histological findings [27]. This finding is controversial, because it is known that strains with s1 genotype produce much greater amounts of toxins. Subtypes of vacA s1 region may be closely related to histological parameters. Nevertheless, Atherton et al. suggested that s1a genotype is associated with peptic ulcer and more severe gastritis [28]. Our results indicate that oipA-positive patients were strongly associated with higher neutrophil activity and *H. pylori* density in gastric biopsy specimens. oipA expression was reported to be linked to severe inflammation and the induction

of IL-8 secretion and the presence of a functional gene is significantly associated with the presence of duodenal ulcers, gastric cancer, and increased neutrophil infiltration [29,30]. Recent work using Mongolian gerbils infected with wild-type *H. pylori* and an isogenic oipA mutant strain demonstrated a role for oipA in induction of the mucosal cytokines IL-1, IL-17, and tumor necrosis factor alpha (TNF- α) and in gastric mucosal inflammation [31]. In the present study, iceA1 allele was predominant and was not associated with the severity of the gastritis. Besides the virulence factors of *H. pylori*, variations of acid production, the genetics of the infected subject, tobacco and alcohol intake may affect both clinical outcomes and the histopathological findings. More studies are needed to evaluate other factors besides the *H. pylori* genotypes, because *H. pylori* is thought to be a cause of serious diseases.

Acknowledgments

This study was financially supported by research deputy of Shahrekord University of Medical Sciences (Grant no. 1025). The authors are grateful to the staffs of Cellular & Molecular Research Center, Shahrekord University of Medical Sciences and the authorities of the endoscopy unit of Shahrekord Hajar Hospital for their valuable helps.

References

- [1] K.E. McColl, Clinical practice. *Helicobacter pylori* infection, N. Engl. J. Med. 362 (17) (2010 Apr 29) 1597–1604.
- [2] J.M. Taylor, M.E. Ziman, D.R. Canfield, M. Vajdy, J.V. Solnick, Effects of a Th1-versus a Th2-biased immune response in protection against *Helicobacter pylori* challenge in mice, Microb. Pathog. 44 (1) (2008 Jan) 20–27.
- [3] T.P. Cid, M.C. Fernandez, Benito Martinez S, Jones NL. Pathogenesis of *Helicobacter pylori* infection, Helicobacter 18 (Suppl. 1) (2013 Sep) 12–17.
- [4] N. Bagheri, A. Taghikhani, G. Rahimian, L. Salimzadeh, F. Azadegan Dehkordi, F. Zandi, et al., Association between virulence factors of *Helicobacter pylori* and gastric mucosal interleukin-18 mRNA expression in dyspeptic patients, Microb. Pathog. 65 (2013 Dec) 7–13.
- [5] G. Rahimian, M.H. Sanei, H. Shirzad, F. Azadegan-Dehkordi, A. Taghikhani, L. Salimzadeh, et al., Virulence factors of *Helicobacter pylori* vacA increase markedly gastric mucosal TGF- β 1 mRNA expression in gastritis patients, Microb. Pathog. 67–68 (2014) 1–7.
- [6] D. Basso, M.H. Plebani, *pylori* infection: bacterial virulence factors and cytokine gene polymorphisms as determinants of infection outcome, Crit. Rev. Clin. Lab. Sci. 41 (3) (2004) 313–337.
- [7] Q. Qadri, D. Afroz, R. Rasool, G.M. Gulzar, S. Naqash, M.A. Siddiqi, et al., CagA subtyping in *Helicobacter pylori* isolates from gastric cancer patients in an ethnic Kashmiri population, Microb. Pathog. 66 (2014 Jan) 40–43.
- [8] L.E. Wroblewski, R.M. Peek Jr., K.T. Wilson, *Helicobacter pylori* and gastric cancer: factors that modulate disease risk, Clin. Microbiol. Rev. 23 (4) (2010 Oct) 713–739.
- [9] M.Y. Wang, C. Chen, X.Z. Gao, J. Li, J. Yue, F. Ling, et al., Distribution of *Helicobacter pylori* virulence markers in patients with gastroduodenal diseases in a region at high risk of gastric cancer, Microb. Pathog. 59–60 (2013 Jun–Jul) 13–18.
- [10] N. Amjad, H.A. Osman, N.A. Razak, J. Kassian, J. Din, N. bin Abdullah, Clinical significance of *Helicobacter pylori* cagA and iceA genotype status, World J. Gastroenterol. 16 (35) (2010 Sep 21) 4443–4447.
- [11] K. Torres, E. Valderrama, M. Sayegh, J.L. Ramirez, M.A. Chiurillo, Study of the oipA genetic diversity and EPIYA motif patterns in cagA-positive *Helicobacter pylori* strains from Venezuelan patients with chronic gastritis, Microb. Pathog. 76C (2014 Sep 16) 26–32.
- [12] E. Ogorodnik, R.D. Raffaniello, Analysis of the 3'-variable region of the cagA gene from *Helicobacter pylori* strains infecting patients at New York City hospitals, Microb. Pathog. 56 (2013 Mar) 29–34.
- [13] N. Bagheri, G. Rahimian, L. Salimzadeh, F. Azadegan, M. Rafeian-Kopaei, A. Taghikhani, et al., Association of the virulence factors of *Helicobacter pylori* and gastric mucosal interleukin-17/23 mRNA expression in dyspeptic patients, EXCLI J. 12 (2013) 5–14.
- [14] Y. Yamaoka, T. Kodama, M. Kita, J. Imanishi, K. Kashima, D.Y. Graham, Relationship of vacA genotypes of *Helicobacter pylori* to cagA status, cytotoxin production, and clinical outcome, Helicobacter 3 (4) (1998 Dec) 241–253.
- [15] D. Ilver, A. Arnqvist, J. Ogren, I.M. Frick, D. Kersulyte, E.T. Incecik, et al., *Helicobacter pylori* adhesin binding fucosylated histo-blood group antigens revealed by retagging, Science 279 (5349) (1998 Jan 16) 373–377.
- [16] M. Gerhard, N. Lehn, N. Neumayer, T. Boren, R. Rad, W. Schepp, et al., Clinical relevance of the *Helicobacter pylori* gene for blood-group antigen-binding adhesin, Proc. Natl. Acad. Sci. U. S. A. 96 (22) (1999 Oct 26) 12778–12783.

- [17] L.J. van Doorn, C. Figueiredo, R. Sanna, A. Plaisier, P. Schneeberger, W. de Boer, et al., Clinical relevance of the *cagA*, *vacA*, and *iceA* status of *Helicobacter pylori*, *Gastroenterology* 115 (1) (1998 Jul) 58–66.
- [18] Y. Yamaoka, S. Kikuchi, H.M. el-Zimaity, O. Gutierrez, M.S. Osato, D.Y. Graham, Importance of *Helicobacter pylori* *oipA* in clinical presentation, gastric inflammation, and mucosal interleukin 8 production, *Gastroenterology* 123 (2) (2002 Aug) 414–424.
- [19] M.F. Dixon, R.M. Genta, J.H. Yardley, P. Correa, Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994, *Am. J. Surg. Pathol.* 20 (1996) 1161–1181.
- [20] N. Bagheri, F. Azadegan-Dehkordi, H. Sanei, A. Taghikhani, G. Rahimian, L. Salimzadeh, et al., Associations of a TLR4 single-nucleotide polymorphism with *H. pylori* associated gastric diseases in Iranian patients, *Clin. Res. Hepatol. Gastroenterol.* 38 (3) (2014) 366–371.
- [21] L. Demirturk, A.M. Ozel, Y. Yazgan, E. Solmazgul, S. Yildirim, M. Gultepe, et al., CagA status in dyspeptic patients with and without peptic ulcer disease in Turkey: association with histopathologic findings, *Helicobacter* 6 (2) (2001 Jun) 163–168.
- [22] M. Saruc, M.A. Demir, N. Kucukmetin, A.R. Kandiloglu, U.S. Akarca, H. Yuceyar, Histological and clinical predictive value of determination of tissue CagA status by PCR in *Helicobacter pylori* infected patients; results of the large population based study in western Turkey, *Hepatogastroenterology* 49 (45) (2002 May–Jun) 878–881.
- [23] Z. Khodaii, S.M. Ghaderian, R. Akbarzadeh Najari, H. Nejati, A.S. Tabatabaei Panah, *cagA* and *vacA* status and influence of *Helicobacter pylori* infection on serum oxidative DNA damage in Iranian patients with peptic ulcer disease, *Ir. J. Med. Sci.* 180 (1) (2011 Mar) 155–161.
- [24] H.J. Tan, A.M. Rizal, M.Y. Rosmadi, K.L. Goh, Distribution of *Helicobacter pylori* *cagA*, *cagE* and *vacA* in different ethnic groups in Kuala Lumpur, Malaysia, *J. Gastroenterol. Hepatol.* 20 (4) (2005 Apr) 589–594.
- [25] Y. Yamaoka, T. Kodama, O. Gutierrez, J.G. Kim, K. Kashima, D.Y. Graham, Relationship between *Helicobacter pylori* *iceA*, *cagA*, and *vacA* status and clinical outcome: studies in four different countries, *J. Clin. Microbiol.* 37 (7) (1999 Jul) 2274–2279.
- [26] S. Miehke, C. Kirsch, K. Agha-Amiri, T. Gunther, N. Lehn, P. Malfertheiner, et al., The *Helicobacter pylori* *vacA* s1, m1 genotype and *cagA* is associated with gastric carcinoma in Germany, *Int. J. Cancer* 87 (3) (2000 Aug 1) 322–327.
- [27] V.J. Warburton, S. Everett, N.P. Mapstone, A.T. Axon, P. Hawkey, M.F. Dixon, Clinical and histological associations of *cagA* and *vacA* genotypes in *Helicobacter pylori* gastritis, *J. Clin. Pathol.* 51 (1) (1998 Jan) 55–61.
- [28] J.C. Atherton, R.M. Peek Jr., K.T. Tham, T.L. Cover, M.J. Blaser, Clinical and pathological importance of heterogeneity in *vacA*, the vacuolating cytotoxin gene of *Helicobacter pylori*, *Gastroenterology* 112 (1) (1997 Jan) 92–99.
- [29] T. Ando, R.M. Peek, D. Pride, S.M. Levine, T. Takata, Y.C. Lee, et al., Polymorphisms of *Helicobacter pylori* HP0638 reflect geographic origin and correlate with *cagA* status, *J. Clin. Microbiol.* 40 (1) (2002 Jan) 239–246.
- [30] A.T. Franco, E. Johnston, U. Krishna, Y. Yamaoka, D.A. Israel, T.A. Nagy, et al., Regulation of gastric carcinogenesis by *Helicobacter pylori* virulence factors, *Cancer Res.* 68 (2) (2008 Jan 15) 379–387.
- [31] M. Sugimoto, T. Ohno, D.Y. Graham, Y. Yamaoka, Gastric mucosal interleukin-17 and -18 mRNA expression in *Helicobacter pylori*-induced Mongolian gerbils, *Cancer Sci.* 100 (11) (2009 Nov) 2152–2159.